CancerDrs

Leukemia clinical trials in Utah

25 actively recruiting leukemia trials at 9 sites across Utah.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Utah:
  • American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
  • Sandra L Maxwell Cancer Center — Cedar City, Utah
  • Logan Regional Hospital — Logan, Utah
  • Intermountain Medical Center — Murray, Utah
  • McKay-Dee Hospital Center — Ogden, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Utah:
  • Intermountain Healthcare LDS Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
  • George E Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
  • George E Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…

Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT ID: NCT06163430
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …

Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Utah:
  • University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Utah:
  • Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07605416
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect again…

Sponsor: University of Utah
NCT ID: NCT05183854
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886049
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up…

Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT04771572
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic ly…

Sponsor: Hoffmann-La Roche
NCT ID: NCT05091424
Sites in Utah:
  • Huntsman Cancer Institute at The University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecu…

Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT04775745
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for man…

Sponsor: University of Utah
NCT ID: NCT06227026
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah:
  • Massive Bio SYNERGY-AI site — Salt Lake City, Utah
View on ClinicalTrials.gov →
NA Recruiting NIH

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive thi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05621291
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12